The Department of Health and Human Services (HHS) began to limit the distribution of the antibody therapy for COVID-19 on Sept. 3 to address a surge in demand for the treatment.
The department immediately limited orders only to sites that report their utilization of the monoclonal therapy to the government, according to a notice. The HHS is also vetting all orders against the rate at which the sites are utilizing the allotted doses.
